GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » Margin of Safety % (DCF Earnings Based)

VXRT (Vaxart) Margin of Safety % (DCF Earnings Based) : N/A (As of Mar. 31, 2025)


View and export this data going back to 1990. Start your Free Trial

What is Vaxart Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Vaxart's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Vaxart's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Vaxart's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxart's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Vaxart's Margin of Safety % (DCF Earnings Based) falls into.


;
;

Vaxart Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Vaxart's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxart Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » Margin of Safety % (DCF Earnings Based)
Comparable Companies
ADVM ANIX ACHV GALT EXOZ CHRS FATE XBIT VOR RENB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
NB11:Germany NB11:Germany
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Website
https://www.vaxart.com
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Executives
W. Mark Watson director 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Phillip E Lee officer: Chief Financial Officer C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Elaine J Heron director 6 STONEGATE RD, PONTOLA VALLEY CA 94028
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Edward B Berg officer: SVP, General Counsel C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Robert A. Yedid director C/O LIFESCI ADVISORS, 250 WEST 55TH STREET, SUITE 3401, NEW YORK NY 10019
Margaret Echerd officer: VP, Corporate Controller, PAO 3585 MONROE STREET, SANTA CLARA CA 95051
James F. Cummings officer: Chief Medical Officer 1312 BEACHVIEW ROAD, ANNAPOLIS MD 21403
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Sean Tucker officer: Chief Scientific Officer 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
Wouter Latour director, officer: President and Chief Executive 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037